ACT has established a partnership with the University of Louisville’s James Graham Brown Cancer Center whereby the company is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at the Center under preset business terms. ACT then advances these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry.
This round, which comes from Kentucky-based high net-worth individuals and institutions, will provide additional capital to continue the development and commercialization of potentially lifesaving therapeutics for cancer patients.
ACT’s top priority programs include novel small molecule compound inhibitors for:
– PFKFB3, which is the enzyme involved in the first irreversible step of glycolysis,
– Choline Kinase, which is the enzyme responsible for the phosphorylation of choline into phosphocholine, and is over expressed in most solid tumors including lung, breast, ovarian, brain and prostate cancers.
In addition, the company is advancing PU27, a sequence specific DNA oligonucleotide that inhibits cancer cell proliferation and appears well tolerated from a recently completed preliminary animal toxicology study.